One possible explanation is that PKM2 interacts with the CDK1-cyclinB complex to facilitate cell cycle progression in gliomas, and knockdown of PKM2 decreases CDK1 kinase activity (39). This evidence concerns the gene CDK1 and central nervous system cancer.